To provide a toolkit of information for hospitals to use in developing intravenous to oral conversion protocols for antihypertensives.
Data Sources:
Articles describing intravenous to oral conversion protocols for any therapeutic category were identified in an English-language MEDLINE search (1990-April 2010) using a wide variety of MeSH terms. References from selected articles were reviewed for additional material.
Study Selection and Data Extraction:
Experimental and observational English-language studies and review articles that focused on oral transition of intravenous drugs were selected.
Data Synthesis:
Most of the literature on conversion from intravenous to oral formulations involves antimicrobials. There is considerable evidence documenting reduced costs and improved patient flow through the health-care system following implementing these protocols with drugs like antimicrobials, histamine-2 receptor antagonists, and proton pump inhibitors. Although antihypertensives have not been studied, principles and implementation strategies used for other drug classes can be applied to antihypertensives. Guidance is provided on framing the problem, issues surrounding oral absorption principles, information pertaining to oral conversion in specific disease slates, and implementation and documentation strategies. Detailed tables of oral and intravenous antihypertensives are provided.
Conclusions:
We recommend that hospitals consider developing protocols on conversion of intravenous to oral antihypertensives in an attempt to reduce unnecessarily prolonged intravenous therapy. Information contained in this article can be used as a toolkit to select information specific to the characteristics of individual health-care systems.
DastaJ, KimSR, McLaughlinTP, ModyS, PiechCT. Incremental daily cost of mechanical ventilation in patients receiving treatment in an intensive care unit. Crit Care Med2005; 33:1266–71.
AthanassaZ, MakrisG, DimopoulosG, FalagasME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia. Drugs2008; 68:2469–81.
4.
FischerMA, SolomonDH, TeichJM, AvornJ. Conversion from intravenous to oral medications. Arch Intern Med2003; 163:2585–9.
5.
KatzJN, GoreJM, AminA, on behalf of the STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: results from the Studying the Treatment of Acute hyperTension Registry. Am Heart J2009; 158:599–606.
6.
BensonJ, GerlachA, DastaJ. National survey of acute hypertension management. Crit Care Shock2008; 11:154–66.
7.
AdamsHP, del ZoppoG, AlbertsMJ. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke2007; 38:1655–711.
8.
BroderickJ, ConnollyS, FeldmannE. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke2007; 38:2001–23.
9.
ChobanianAV, BakrisGL, BlackHR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003; 289:2560–72.
10.
RhoneyD, PeacockF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm2009; 66:1343–52.
11.
RhoneyD, PeacockF. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm2009; 66:1448–57.
12.
QuershiAI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation2008; 118:176–87.
13.
VaronJ. Treatment of acute severe hypertension. Drags2008; 68:283–97.
AnaduU, EroweleGI, EbiasahR, GreenW. Clevidipine: a new intravenous option for the management of acute hypertension. Am J Health Syst Pharm2010; 67:351–60.
16.
PaladinoJA, SperryHE, BackesJM. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med1991; 91:462–70.
17.
BancoH, GoldwaterSH, AdamsE. Smoothing the path for intravenous to oral conversion: where have we come in 11 years?Hosp Pharm2009; 44:959–67.
18.
MartinSJ, CloseSJ. Fluoroquinolone-associated length of stay reduction in the hospital treatment of community-acquired pneumonia. Infect Dis Clin Pract2003; 11:540–9.
GrahamDJM, DowRJ, HallDJ, AlexanderF, MroszczakEJ, FreedmanD. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol1985; 20:23S–8S.
27.
Product information.Cleviprex (clevidipine). Parsippany, NJ: The Medicines Company, August2008.
ChobanianAV, BakrisGL, BlackHR.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: seventh report of the Joint Committee on detection, evaluation and treatment of high blood pressure [JNC-VII]. Hypertension42:12062003.
35.
HamblinS, FurmanekD, CassA. Optimal methods of transitioning from intravenous to oral antihypertensives: a pilot study (abstract 878). Crit Care Med2009; 37:A430.
36.
BoucherBA, WoodGC, SwansonJM. Pharmacokinetic changes in critical illness. Crit Care Clin2006; 22:255–71.
37.
PeaF, PavanF, FurlanutM. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet2008; 47:449–62.
38.
WilliamsNT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm2008; 65:2347–57.
39.
MagnusonBL, CliffordTM, HoskinsLA, BernardAC. Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract2005; 20:618–24.
40.
DickersonRN, TidwellAC, BrownRO. Adverse effects from inappropriate medication administration via a jejunostomy feeding tube. Nutr Clin Pract2003; 18:402–5.
41.
PhillipsNM, NatR. A systematic review of nursing administration of medication via enteral tubes in adults. J Clin Nurs2008; 17:2257–65.
42.
Micromedex 1.0 Healthcare Series. Greenwood Village, CO: Thomson Reuters Healthcare Inc. (accessed 2009 Nov 11).
43.
VogelF. Intravenous/oral sequential therapy in patients hospitalized with community-acquired pneumonia: which patients, when and what agents?Drugs2002; 62:309–17.
44.
LudwigK, EnkerWE, DelaneyCP. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg2008; 143:1098–105.
45.
DelaneyCP, WeeseJL, HymanNH. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum2005; 48:1114–25.
46.
WolffBG, MichelassiF, GerkinTM. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg2004; 240:728–35.
47.
BuchlerMW, SeilerCM, MonsonJRT. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol2008; 28:312–5.
48.
McClaveSA, MartindaleRG, VanekVW. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr2009; 33:277–316.
49.
WongND, LopezVA, L'ItalienG, ChenR, KlineSE, FranklinSS. Inadequate control of hypertension in US adults with cardiovascular disease co-morbidities in 2003-2004. Arch Intern Med2007; 167:2431–6.
50.
LuddenTM, ShepherdAM, McNayJL. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther1980; 28:736–42.
51.
KramerAH, BleckTP. Acute hypertension management in the ICU. In: GabrielliA, LayonAJ, YuM., eds. Critical care. Philadelphia: Wolters KIuwer/Lippincott Williams & Wilkins, 2009: 1887–98.
52.
HalaszynskiTM, JudaR, SilvermanDG. Optimizing postoperative outcomes with efficient preoperative assessment and management. Crit Care Med2004; 32:S76–86.
53.
Leonardi-BeeJ, BathPMW, PhillipsSJ, SandercockPAG. Blood pressure and clinical outcomes in the international stroke trial. Stroke2002; 33:1315–20.
54.
PotterJF, RobinsonTG, FordGA. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomized, placebo-controlled, double-blind pilot trial. Lancet Neurol2009; 8:48–56.
55.
SchraderJ, LudersS, KulschewskiA. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke2003; 34:1699–703.
56.
EvesonDJ, RobinsonTG, PotterJF. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens2007; 20:270–7.
57.
ThomasD, BathPM, LeesK, for the ENOS Trial Investigators. Glyceryl trinitrate vs control, and continuing vs stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the efficacy of nitric oxide in stroke (ENOS) trial (ISRCTN99414122). Int J Stroke2006; 1:245–9.
58.
COSSACS Trial Group.COSSACS (Continue or Stop post-Stroke Antihypertensives Collaborative Study): rationale and design. J Hypertens2005; 23:455–8.
59.
PapademetriouV, FarsangC, ElmfeldtD, for the SCOPE Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Colf Cardiol2004; 44:1175–80.
60.
PROGRESS Collaborative group.Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033–41.
61.
The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000; 342:145–53.
62.
JamersonK, WeberMA, BakrisGL, for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med2008; 359:2417–28.
63.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002; 288:2981–97.
64.
GoldwaterSH, Heal-JaniferA, MilkovichG, ChatelainF. Smoothing the path for IV-to-oral conversion. Am J Health Syst Pharm1997; 54:200–5.
65.
Wong-BeringerA, NguyenK-H, RazeghiJ. Implementing a program for switching from IV to oral antimicrobial therapy. Am J Health Syst Pharm2001; 58:1146–9.
66.
ZaminMT, PitreMM, ConlyJM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother1997; 31:564–70.
67.
EhrenkranzNJ, NerenbergDE, ShultzJM, SlaterKC. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening of stay. Infect Control Hosp Epidemiol1992; 13:21–5.
68.
PrzybylskiKG, RybakMJ, MartinPR. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy1997; 17:271–6.
69.
RobertsBL. Decentralizing an IV to oral conversion program. Am J Hosp Pharm1997; 54:524–5.
